Table 1.
List of reported ATG4B regulators.
Name/Compound ID | IC50 | Methods | Effect on ATG4B | Effect on Autophagy | Effect on Cancer | Ref. |
---|---|---|---|---|---|---|
201508 | 2.3 µM | LC3B-PLA2 assay | Inhibiting | N.R. | N.R. | [107] |
1502245 | 3.0 µM | LC3B-PLA2 assay | Inhibiting | N.R. | N.R. | [107] |
1504078 | 1.7 µM | LC3B-PLA2 assay | Inhibiting | N.R. | N.R. | [107] |
1504080 | 1.1 µM | LC3B-PLA2 assay | Inhibiting | N.R. | N.R. | [107] |
Tioconazole | 1.8 µM | LC3B-PLA2 assay | Inhibiting | Inhibiting | Enhancing Dox-induced cytotoxicity in colorectal cancer | [44] |
Z-FA-FMK | 14.8 µM | TR-FRET assay | Inhibiting | N.R. | N.R. | [100] |
Z-FG-FMK | 1.13 µM | TR-FRET assay | Inhibiting | N.R. | N.R. | [100] |
FMK-9a | 80 nM | TR-FRET assay | Inhibiting | Inducing | Having no effect on the survival of HeLa cells | [101,108] |
Hypericin | 30 µM | FRET assay | Inhibiting | N.R. | N.R. | [109] |
Aurin | 8.8 µM | FRET assay | Inhibiting | N.R. | N.R. | [109] |
LV-320 | 24.5 µM | Fluorescent peptide substrate assay | Inhibiting | Inhibiting | N.R. | [103] |
UAMC-2526 | N.R. | LC3-GST cleavage assay | Inhibiting | Inhibiting | Enhancing Oxaliplatin-induced cytotoxicity in colorectal cancer | [110] |
NSC185058 | 51 µM | In silico screening, LC3-GST cleavage assay | Inhibiting | Inhibiting | Suppressing the development ofSao-2 cells; enhancing the anti-glioblastoma activity of radiation therapy | [31,62] |
S130 | 3.2 µM | In silico screening, FRET assay | Inhibiting | Inhibiting | Arresting the growth of colorectal cancer | [6] |
Flubendazole | N.R. | In silico analysis | Inducing | Inducing | Inducing autophagic cell death in MDA-MB-231 cells | [102] |
N.R.: not reported.